Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
Cancers · 27.07.2023 · 15 (15) · 3815
DOI: 10.3390/cancers15153815 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.07.2023. Verfasst von Margo B Gerke und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Emory University, Atlanta, GA 30322, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) are hematological disorders characterized by both proliferative and dysplastic features. According to the 2022 International Consensus Classification (ICC), MDS/MPN consists of clonal monocytosis of undetermined significance (CMUS), chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (aCML), MDS/MPN with SF3B1 mutation (MDS/MPN-T-SF3B1), MDS/MPN with ring sideroblasts and thrombocytosis not otherwise specified (MDS/MPN-RS-T-NOS), and MDS/MPN-NOS. These disorders exhibit a diverse range of genetic alterations involving various transcription factors (e.g., RUNX1), signaling molecules (e.g., NRAS, JAK2), splicing factors (e.g., SF3B, SRSF2), and epigenetic regulators (e.g., TET2, ASXL1, DNMT3A), as well as specific cytogenetic abnormalities (e.g., 8 trisomies, 7 deletions/monosomies). Clinical studies exploring therapeutic options for higher-risk MDS/MPN overlap syndromes mostly involve hypomethylating agents, but other treatments such as lenalidomide and targeted agents such as JAK inhibitors and inhibitors targeting PARP, histone deacetylases, and the Ras pathway are under investigation. While these treatment modalities can provide partial disease control, allogeneic bone marrow transplantation (allo-BMT) is the only potentially curative option for patients. Important prognostic factors correlating with outcomes after allo-BMT include comorbidities, splenomegaly, karyotype alterations, and the bone marrow blasts percentage at the time of transplantation. Future research is imperative to optimizing therapeutic strategies and enhancing patient outcomes in MDS/MPN neoplasms. In this review, we summarize MDS/MPN diagnostic criteria, biology, and current and future treatment options, including bone marrow transplantation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medicine, Emory University, Atlanta, GA 30322, USA.
- Department of Medicine, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Department of Oncology, Johns Hopkins University, Baltimore, MD 21218, USA.
ORCID-Profile: Margo B Gerke, Ilias Christodoulou, Theodoros Karantanos
Förderung
- NHLBI NIH HHS
Zitieren
APA
Gerke, M. B., Christodoulou, I., & Karantanos, T. (2023). Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Cancers, 15(15), 3815. https://doi.org/10.3390/cancers15153815
Vancouver
Gerke MB, Christodoulou I, Karantanos T. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms. Cancers. 2023;15(15):3815. doi:10.3390/cancers15153815
BibTeX
@article{Gerke2023,
author = {Gerke, Margo B and Christodoulou, Ilias and Karantanos, Theodoros},
title = {Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms},
journal = {Cancers},
year = {2023},
volume = {15},
number = {15},
pages = {3815},
doi = {10.3390/cancers15153815}
}
EUVIMED